Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Iveric Bio Inc
(NQ:
ISEE
)
39.95
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 10, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Iveric Bio Inc
< Previous
1
2
3
4
Next >
Iveric Bio to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022
February 17, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
February 11, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces New Post-Hoc Analyses of Zimura® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Exudation, and Degeneration 2022
February 07, 2022
From
IVERIC Bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors
January 06, 2022
From
Iveric Bio
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Present at the H.C. Wainwright BioConnect Virtual Conference
January 04, 2022
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Appoints Tony Gibney as Executive Vice President and Chief Business and Strategy Officer
December 13, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Participate in the Stifel 2021 Virtual Healthcare Conference
November 10, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Third Quarter 2021 Operational Highlights and Financial Results
November 09, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Participate in the Credit Suisse 30th Annual Virtual Healthcare Conference
November 03, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Report Third Quarter 2021 Financial Results and Host Conference Call on Tuesday, November 9, 2021
November 02, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock
October 21, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Announces Proposed Offering of Common Stock
October 21, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Present at the H.C. Wainwright Ophthalmology Virtual Conference
August 10, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021
August 04, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results
August 04, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 03, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Report Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
July 28, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule
July 26, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Appoints Christopher Simms as Chief Commercial Officer
July 19, 2021
From
IVERIC bio, Inc.
Via
Business Wire
IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
July 12, 2021
From
IVERIC bio, Inc.
Via
Business Wire
IVERIC bio, Inc. Announces Proposed Offering of Common Stock
July 12, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
July 06, 2021
From
IVERIC bio, Inc.
Via
Business Wire
Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium for Investors
June 18, 2021
From
IVERIC bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.